These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 21453200)

  • 1. Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy.
    Galino J; Ruiz M; Fourcade S; Schlüter A; López-Erauskin J; Guilera C; Jove M; Naudi A; García-Arumí E; Andreu AL; Starkov AA; Pamplona R; Ferrer I; Portero-Otin M; Pujol A
    Antioxid Redox Signal; 2011 Oct; 15(8):2095-107. PubMed ID: 21453200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy.
    López-Erauskin J; Galino J; Ruiz M; Cuezva JM; Fabregat I; Cacabelos D; Boada J; Martínez J; Ferrer I; Pamplona R; Villarroya F; Portero-Otín M; Fourcade S; Pujol A
    Hum Mol Genet; 2013 Aug; 22(16):3296-305. PubMed ID: 23604518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Astrocytes and mitochondria from adrenoleukodystrophy protein (ABCD1)-deficient mice reveal that the adrenoleukodystrophy-associated very long-chain fatty acids target several cellular energy-dependent functions.
    Kruska N; Schönfeld P; Pujol A; Reiser G
    Biochim Biophys Acta; 2015 May; 1852(5):925-36. PubMed ID: 25583114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence of oxidative stress in very long chain fatty acid--treated oligodendrocytes and potentialization of ROS production using RNA interference-directed knockdown of ABCD1 and ACOX1 peroxisomal proteins.
    Baarine M; Andréoletti P; Athias A; Nury T; Zarrouk A; Ragot K; Vejux A; Riedinger JM; Kattan Z; Bessede G; Trompier D; Savary S; Cherkaoui-Malki M; Lizard G
    Neuroscience; 2012 Jun; 213():1-18. PubMed ID: 22521832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy.
    Morató L; Galino J; Ruiz M; Calingasan NY; Starkov AA; Dumont M; Naudí A; Martínez JJ; Aubourg P; Portero-Otín M; Pamplona R; Galea E; Beal MF; Ferrer I; Fourcade S; Pujol A
    Brain; 2013 Aug; 136(Pt 8):2432-43. PubMed ID: 23794606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy.
    López-Erauskin J; Fourcade S; Galino J; Ruiz M; Schlüter A; Naudi A; Jove M; Portero-Otin M; Pamplona R; Ferrer I; Pujol A
    Ann Neurol; 2011 Jul; 70(1):84-92. PubMed ID: 21786300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.
    Singh J; Khan M; Singh I
    J Lipid Res; 2011 Nov; 52(11):2056-69. PubMed ID: 21891797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeic acid phenethyl ester induces adrenoleukodystrophy (Abcd2) gene in human X-ALD fibroblasts and inhibits the proinflammatory response in Abcd1/2 silenced mouse primary astrocytes.
    Singh J; Khan M; Singh I
    Biochim Biophys Acta; 2013 Apr; 1831(4):747-58. PubMed ID: 23318275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol regulates ABCD2 expression: implications for the therapy of X-linked adrenoleukodystrophy.
    Weinhofer I; Forss-Petter S; Zigman M; Berger J
    Hum Mol Genet; 2002 Oct; 11(22):2701-8. PubMed ID: 12374760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.
    Baarine M; Beeson C; Singh A; Singh I
    J Neurochem; 2015 May; 133(3):380-96. PubMed ID: 25393703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative stress modulates mitochondrial failure and cyclophilin D function in X-linked adrenoleukodystrophy.
    López-Erauskin J; Galino J; Bianchi P; Fourcade S; Andreu AL; Ferrer I; Muñoz-Pinedo C; Pujol A
    Brain; 2012 Dec; 135(Pt 12):3584-98. PubMed ID: 23250880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical aspects of X-linked adrenoleukodystrophy.
    Kemp S; Wanders R
    Brain Pathol; 2010 Jul; 20(4):831-7. PubMed ID: 20626744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy.
    Schlüter A; Espinosa L; Fourcade S; Galino J; López E; Ilieva E; Morató L; Asheuer M; Cook T; McLaren A; Reid J; Kelly F; Bates S; Aubourg P; Galea E; Pujol A
    Hum Mol Genet; 2012 Mar; 21(5):1062-77. PubMed ID: 22095690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial dysfunction and oxidative damage cooperatively fuel axonal degeneration in X-linked adrenoleukodystrophy.
    Fourcade S; López-Erauskin J; Ruiz M; Ferrer I; Pujol A
    Biochimie; 2014 Mar; 98():143-9. PubMed ID: 24076127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy.
    Fourcade S; López-Erauskin J; Galino J; Duval C; Naudi A; Jove M; Kemp S; Villarroya F; Ferrer I; Pamplona R; Portero-Otin M; Pujol A
    Hum Mol Genet; 2008 Jun; 17(12):1762-73. PubMed ID: 18344354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accumulation of very long-chain fatty acids does not affect mitochondrial function in adrenoleukodystrophy protein deficiency.
    Oezen I; Rossmanith W; Forss-Petter S; Kemp S; Voigtländer T; Moser-Thier K; Wanders RJ; Bittner RE; Berger J
    Hum Mol Genet; 2005 May; 14(9):1127-37. PubMed ID: 15772093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy.
    Monternier PA; Parasar P; Theurey P; Gluais Dagorn P; Kaur N; Nagaraja TN; Fouqueray P; Bolze S; Moller DE; Singh J; Hallakou-Bozec S
    J Pharmacol Exp Ther; 2022 Aug; 382(2):208-222. PubMed ID: 35764327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy.
    Fourcade S; Ruiz M; Guilera C; Hahnen E; Brichta L; Naudi A; Portero-Otín M; Dacremont G; Cartier N; Wanders R; Kemp S; Mandel JL; Wirth B; Pamplona R; Aubourg P; Pujol A
    Hum Mol Genet; 2010 May; 19(10):2005-14. PubMed ID: 20179078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin-induced mitochondrial function and ABCD2 up-regulation in X-linked adrenoleukodystrophy involves AMP-activated protein kinase.
    Singh J; Olle B; Suhail H; Felicella MM; Giri S
    J Neurochem; 2016 Jul; 138(1):86-100. PubMed ID: 26849413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of deuterium-stabilized (R)-pioglitazone-PXL065-for X-linked adrenoleukodystrophy.
    Monternier PA; Singh J; Parasar P; Theurey P; DeWitt S; Jacques V; Klett E; Kaur N; Nagaraja TN; Moller DE; Hallakou-Bozec S
    J Inherit Metab Dis; 2022 Jul; 45(4):832-847. PubMed ID: 35510808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.